Title : Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.

Pub. Date : 2013 Oct

PMID : 23636313






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Activation of the PI3K/AKT/mTOR pathway was related to poor disease outcome in DLBCL patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) but not in those treated with rituximab-CHOP. Cyclophosphamide DNA damage inducible transcript 3 Homo sapiens